Core Diagnostics partners with US-based Paradigm for tumour profiling in India

Indian medical start-up Core Diagnostics has entered into a new partnership with leading US-based molecular diagnostics company Paradigm to bring to India the latter’s advanced cancer profiling service, PCDx, which helps in detailed personalising of each cancer patient’s course of treatment.
 
Paradigm, the molecular information & next generation sequencing (NSG) company specialising in providing tumour analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with Core Diagnostics to facilitate patient access to PCDx, in India. Through this association, the two companies aim to provide a growing community of oncologists the most relevant and actionable cancer care available.
   
With molecular testing driving the new wave of personalised cancer treatment protocols, this agreement with enable Core Diagnostics add a valuable service to its comprehensive menu of advanced diagnostic tests in India.
 
PCDx (Paradigm Cancer Diagnostic) is a comprehensive clinical-grade NGS-based test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumours DNA, RNA & Protein. The test interrogates the most relevant genomic targets at over 5,000x average depth of coverage with 72 therapeutic associations. Results are typically delivered in 4-5 business days.
 
The test uses molecular data to help oncologists provide the most effective treatment plan for each patient and devise more accurate therapeutic options for patient care.
 
“With a focus on esoteric testing, an extensive experience in the region, and a dedicated diagnostics sales team of over 40, Core is an ideal partner to Paradigm as it seeks to expand the reach of its PCDx tumour profiling service. Paradigm’s offering would be a great addition to our portfolio. We are looking forward to this relationship with Paradigm and believe it will have a significant impact on improving the treatment of cancer patients in India,” said Zoya Brar, founder & managing director of Core Diagnostics.
 
David Mallery, president, Paradigm, said, “Expanding our testing services outside the US market is a key strategic initiative for Paradigm. The relationship with Core Diagnostics provides us with considerable resources to rapidly expand testing and realise this goal while allowing better patient and physician access to PCDx abroad.”
 
Core Diagnostics, offers a comprehensive menu of specialised, advanced diagnostic testing in India in the areas of cardiology, oncology, reproductive disorders, endocrinology and infectious diseases. It is also working with physicians from prominent medical centers in the US to collaborate with their Indian colleagues. The company deploys next generation sequencing and other technologies in clinical applications and uses digital pathology for enabling concurrent global review of test results. The company also provides patients with peace of mind by delivering second opinions on all cases by at least two specialists from a global panel of pathologists.